FDA Commissioner Marty Makary Resigns Amid Political Pressure

Marty Makary is stepping down as Commissioner of the Food and Drug Administration (FDA) following intense pressure from the Trump administration and conservative lawmakers. President Donald Trump announced the departure on May 12, 2026, stating that Deputy Commissioner Kyle Diamantas will lead the agency in an acting capacity. Makary’s tenure was marked by significant controversy, including disputes over the approval of flavored vapes and the handling of abortion medication regulations. Despite signing a review of mifepristone safety, his subsequent approval of a generic version angered anti-abortion advocates, who demanded his resignation. Senators Bill Cassidy and Josh Hawley publicly welcomed the exit, criticizing Makary for insufficient support of pro-life initiatives. The FDA has faced turbulence under the current administration, including substantial staff reductions driven by the Department of Government Efficiency and the departure of senior officials. Makary’s exit leaves key leadership positions vacant, including directors for major evaluation centers. This development occurs as the agency prepares to discuss the 2027 budget proposal, highlighting ongoing instability within the federal health regulator during a period of heightened political scrutiny over reproductive rights and regulatory policies.